FLGT News & Events

Fulgent Genetics "announced it presented updated data in the Head and Neck Cancer Track during the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting Rapid Oral Abstract Session, scheduled from 4:30 p.m. to 6:00 p.m. CDT in Hall D1 at McCormick Place in Chicago. The abstract, entitled "FID-007 in combination with cetuximab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma, Abstract #6020," will present updated preliminary data from the Company's open-label, randomized Phase 2 study. The study is evaluating the efficacy of two dosing regimens and characterizing the pharmacokinetics, safety, and tolerability of FID-007 in combination with cetuximab in patients whose disease progressed following PD-1 based immune checkpoint inhibitor therapy. As of the April 16, 2026, data cutoff, FID-007 demonstrated meaningful clinical activity and a manageable safety profile in combination with cetuximab in this target patient population."

Foundation Medicine announced plans to launch FoundationOnePGx, a pharmacogenetic offering to identify genetic differences that influence how medicines are metabolized and processed by the body. FoundationOne PGx will be offered in the United States through a partnership with Fulgent Genetics and will be available to order through the Foundation Medicine portal.

Reports Q1 revenue $71.1M vs $73.5M last year. Ming Hsieh, Chairman of the Board of Directors and Chief Executive Officer, said, "I am encouraged by our first quarter performance and the positive trajectory we are seeing across our businesses so far. Our laboratory services segment delivered solid results, and we continued to make meaningful advances in our therapeutic development pipeline across both clinical candidates, FID-007 and FID-022. We are honored to be selected to present our findings on Phase 2 data for FID-007 with a rapid oral abstract at the 2026 ASCO Annual Meeting."